Immunohistochemical expression and prognostic significance of HIF-1α and VEGF-C in neuroendocrine breast cancer

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5227-5232

  Marton, Ingrid ^a   Knežević, Fabijan ^b,c   Ramić, Snježana ^b   Milošević, Milan ^c   Tomas, Davor ^b,c  

^a Croatian Academy of Medical Sciences   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

HIF 1 ; Neuroendocrine breast carcinoma; VEGF C

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROGESTERONE RECEPTOR; VASCULOTROPIN C;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NEUROENDOCRINE BREAST CANCER; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEUROENDOCRINE TUMORS; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84872584434     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MC, Ferlay J, Ward E and Forman D: Global cancer statistics. Ca Cancer J Clin 61: 69-90, 2011.
2. Anderson WF, Hormuzd AK and Rosenberg PS: Incidence of breast cancer in the United States: Current and future trends. J Natl Cancer Inst 103: 1-6, 2011.
3. Tavassoli FA, Devilee P: World Health Organization Classification of Tumors. Tumors of the Beast and Female Genital Organs. IARC Press, Lyon, France, 2003.
4. Miremadi A, Pinder SE, Lee AH, Bell JA, Paish EC, Wencyk P, Elston CW, Nicholson RI, Blamey RW, Robertson JF and Ellis IO: Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology 40: 215-222, 2002.
5. Sapino A, Righi L, Cassoni P, Papotti M, Gugliotta P and Bussolati G: Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Mod Pathol 14: 768-776, 2001.
6. Dales J-P, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P and Charpin C: Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: Retrospective study in a series of 745 patients. Int J Cancer 116: 734-739, 2005.
7. Al-Mowallad A, Kirwan C, Byrne G, McDowell G, Li C, Stewart A, Al-Qouzi A and Kumar S: Vascular endothelial growth factor-C in patients with breast cancer. In Vivo 21: 549-551, 2007.
8. Schoppmann SF, Fenzl A, Schindl M, Bachleitner-Hofmann T, Nagy K, Gnant M, Horvat R, Jakesz R and Birner P: Hypoxia-inducible factor-α correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat 99: 135-141, 2006.
9. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM and Hayes DF; American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-125, 2007.
10. Semenza GL: Hypoxia, clonal selection, and the role of HIF-1α in tumor progression. Crit Rev Biochem Mol Biol 35: 71-103, 2000.
11. Ryan HE, Poloni M, McNulty W, Elson DGassmann M, Arbeit JM and Johnson RS: Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 60: 4010-4015, 2000.
12. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 399: 271-275, 1999.
13. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G and Oberhuber G: Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60: 4693:4696, 2000.
14. Birner P, Schindl M, Obermair A, Breitenecker G and Oberhuber G: Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: Its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7: 1661-1668, 2001.
15. Birner P, Gatterbauer B,Oberhuber G, Schindl M, Rossler K, Prodinger A, Budka H and Hainfellner JA: Expression of hypoxia-inducible factor-1alpha in oligodendrogliomas: Its impact on prognosis and on neoangiogenesis. Cancer 92: 165-171, 2001.
16. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S and Harris AL: Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer: Relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62: 2493-2497, 2002.
17. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH and Semenza GL: Expression of hypoxia-inducible factor-1α: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916, 2001.
18. Kurokawa T, Miyamoto M, Kato K, Cho Y, Kawarada Y, Hida Y, Shinohara T, Itoh T, Okushiba S, Kondo S and Katoh H: Overexpression of hypoxia-inducible factor 1 α (HIF-1α) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer 89: 1042-1047, 2003.
19. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Hung PM, Hung DP, Gatter KC, Johnson PJ and Harris AL: Coexpression of hypoxia-inducible factors 1 α and 2 α, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8: 2595-2604, 2002.
20. Giatromanolaki A, Koukourakis MI, Sivirdis E, Turley H, Talks K, Pezzella F, Gatter KC and Harris AL: Relation of hypoxia inducible factor 1 α and 2 α in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer 85: 881-890, 2001.
21. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ and van der Wall E: Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node-negative breast carcinoma. Cancer 97: 1573-1580, 2003.
22. Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO and Martin SG: Prognostic significance of vascular endothelial cell growth factors-A, -C and D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 96: 1092-1100, 2007.
23. Gisterek I, Matkowski R, Koźlak J, Duś D, Lacko A, Szelachowska J and Kornafel J: Evaluation of prognostic value of VEGF-C and VEGF-D in breast cancer - 10-year follow-up analysis. Anticancer Res 27: 2797-2802, 2007.
24. Al-Mowallad A, Kirwan C, Byrne G, McDowell G, Li C, Stewart A, Al-Qouzi A and Kumar S: Vascular endothelial growth factor-C in patients with breast cancer. In Vivo 21: 549-551, 2007.
25. Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA, Achen MG and Alitalo K: VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 14: 2087-2096, 2000.
26. Sacewicz M, Lawnicka H, Siejka A, Stepień T, Krupiński R, Komorowski J and Stepień H: Inhibition of proliferation, VEGF secretion of human neuroendocrine tumor cell line NCL-H727 by an antagonist of growth hormone-releasing hormone (GNRH) in vitro. Cancer Lett 268: 120-128, 2008.
27. Monsef N, Helczynski L, Lundwall A, Pahlman S and Anders-Bjartell: Localization of immunoreactive HIF-1α and HIF-2α in neuroendocrine cells of both benign and malignant prostate glands. Prostate 67: 1219-1229, 2007.
28. Mayer RJ: Two steps forward in the treatment of colorectal cancer. N Engl J Med 350: 2406-2408, 2004.
29. Velcheti V, Viswanathan A and Govindan R: The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab. A single institutional Survey. J Thorac Oncol 1: 607-610, 2006.
30. Saif MW: New developments in the treatment of pancreatic cancer. Highlights from the 44th ASCO Annual Meeting. JOP 9: 391-397, 2008.
31. Rini BI: Vascular endothelial growth factor- targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 13: 1098-1106, 2007.
32. Burkhardt JK, Riina H, Shin BJ, Christos P, Kesavabhotla K, Hofstetter CP, Tsiouris AJ and Boockvar JA: Intra-arterial delivery of bevacizumab after blood-brain disruption for the treatment of recurrent glioblastoma: Progression-free survival and overall survival. World Neurosurg 77: 130-134, 2012.
33. Burger RA, Brady MF, Bookman MA, Walker JL, Homesley HD, Fowler J, Monk BJ, Greer BE, Boente M and Liang SX: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 28: 18s (suppl:abstr), 2010.
34. Song H, He R, Wang K, Ruan J, Bao C, Li N, Ji J and Cui D: Anti-HIF-1α antibody-conjugated pluronic triblock copolymers encapsulated with paclitaxel for tumor targeting therapy. Biomaterials 8: 2302-2312, 2010.